Sickle Cell

Blood supply shortages have underscored a need to develop new strategies which limit transfusions and triage blood products.

Valoctocogene roxaparvovec would be the first ever approved gene therapy to treat patients with hemophilia A.

The findings can lead to an alternative pain option for patients with sickle cell disease.

The pandemic has burdened blood drives nationally. A new sickle cell drug keeps patients from needing as many transfusions.

How has the new agent fared in its indicated patients in its first year on the market?

How a decades-long issue has resulted in at-need patients lacking confident, available physicians.

The findings suggest cannabis should be further investigated as an alternative to opioids.

New research shows the anticoagulant binds tightly with the coronavirus’ surface spike protein.

A study shows surveyed patients were nearly twice as likely to be satisfied with the care they receive from a usual clinician than an emergency caregiver.

A streamlined testing procedure in sub-Saharan Africa shows improved infant and newborn patient identification.

A look at the risks patients face due to the pandemic—and what minority patients may face daily.

A look at the quarter of available drugs for the rare disease, and how they fare in relation to evolving understanding of disease effect.

Ken Ataga, MD, discusses new developments in interpreting the condition's progression and effect on patients.

A discussion on unanswered questions and concerns among clinicians related to sickle cell disease and the ongoing COVID-19 pandemic.

The Chief Medical Officer of the Sickle Cell Disease Association of America discusses a recently released care provider advisory from the organization.